Paianprilizumab Injection does not have a therapeutic effect on small cell lung cancer. Small cell lung cancer is a malignant tumor of the lungs originating from the bronchial mucosa or glands, and Paianprilizumab Injection is a humanized immunoglobulin G1 monoclonal antibody (IgG1), which is only indicated for adult patients with refractory or relapsed anaplastic Hodgkin’s lymphoma who have undergone at least the second line of systemic chemotherapy, and it does not have a significant therapeutic effect on small cell lung cancer. Paianprilizumab Injection may cause adverse reactions such as rash, skeletal muscle pain, and anemia. It is prohibited for use in people who are allergic to this drug, and breastfeeding women and pregnant women should also try to avoid using it. The main clinical treatment for small cell lung cancer is radiotherapy combined with chemotherapy, in recent years, immunotargeting drugs and targeted drugs are also gradually incorporated into clinical treatment, the specific use of drugs should be combined with the actual condition of the patient and follow the doctor’s instruction.